Fulminant hyperpyrexia induced by bleomycin.

Area of Science:

• Oncology
• Pharmacology

Background:

• Bleomycin is a chemotherapy agent used in treating various cancers.
• Fever is a common, usually mild side effect of bleomycin administration.
• Fatal hyperpyrexia is a rare but serious adverse event associated with bleomycin.

Observation:

• This case report details a fatal hyperpyrexial reaction to bleomycin in a patient with T-cell lymphoma.
• The patient had no fever response to the initial bleomycin injection given three weeks prior.
• The fatal reaction occurred unexpectedly during subsequent bleomycin therapy.

Findings:

• Fatal hyperpyrexia following bleomycin can occur unpredictably.
• The timing of this severe reaction is not limited to initial administration or following a prior febrile response.

Implications:

• Healthcare professionals, patients, and families must be aware of the unpredictable and potentially lethal nature of bleomycin-induced hyperpyrexia.
• Prompt medical evaluation and intervention are crucial for any patient developing fever after bleomycin administration.
• This highlights the need for continued vigilance and risk management strategies in bleomycin therapy.